Contact Information: Contact: Warren Lancaster +1-203-966-2556 (USA) David Seaton +61 2 9878 0088 (Australia)
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
| Source: Marshall Edwards, Inc.
SYDNEY, AUSTRALIA--(Marketwire - February 8, 2010) - Marshall Edwards, Inc. (NASDAQ : MSHL )
announced that Christopher Naughton had resigned as a member of the Board
of Directors effective February 5, 2010. The Board of Directors intends to
fill the vacancy created by Mr. Naughton's resignation. As a result of Mr.
Naughton's resignation, the size of the Board of Directors has decreased
from five to four members.
About Marshall Edwards
Marshall Edwards, Inc. (NASDAQ : MSHL ) is a specialist oncology company
focused on the clinical development of novel anti-cancer therapeutics.
These derive from a flavonoid technology platform, which has generated a
number of novel compounds characterized by broad ranging activity against a
range of cancer cell types with few side effects. The combination of
anti-tumor cell activity and low toxicity is believed to be a result of the
ability of these compounds to target an enzyme present in the cell membrane
of cancer cells, thereby inhibiting the production of pro-survival proteins
within the cell. Marshall Edwards, Inc. has licensed rights from Novogen
Limited (ASX : NRT ) (NASDAQ : NVGN ) to bring four oncology drugs --
phenoxodiol, triphendiol, NV-143 and NV-128 -- to market globally.
Marshall Edwards, Inc. is majority owned by Novogen, an Australian
biotechnology company that is specializing in the development of
therapeutics based on a flavonoid technology platform. More information on
phenoxodiol and on the Novogen group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com.
Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the U.S. Food and Drug
Administration (the "FDA") as being safe and effective for the intended
use. Statements included in this press release that are not historical in
nature are "forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
You should be aware that our actual results could differ materially from
those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability to
maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.